Analyst Price Target is $14.50
▲ +243.60% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Molecular Templates in the last 3 months. The average price target is $14.50, with a high forecast of $20.00 and a low forecast of $12.00. The average price target represents a 243.60% upside from the last price of $4.22.
Current Consensus is
The current consensus among 3 polled investment analysts is to buy stock in Molecular Templates. This Buy consensus rating has held steady for over two years.
Molecular Templates, Inc. engages in the discovery, development, and commercialization of biologic therapeutics for the treatment of cancers and other serious diseases. It utilizes its proprietary biologic drug platform to design and generate engineered toxin bodies, or ETBs. The company was founded by Eric E. Poma, Jean Gariépy, and Leigh Revers in 2000 and is headquartered in Austin, TX.